398 related articles for article (PubMed ID: 25502158)
21. Diagnosis and recognition of early esophageal neoplasia.
Herszényi L; Pregun I; Tulassay Z
Dig Dis; 2009; 27(1):24-30. PubMed ID: 19439957
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the clinical and histological characteristics and survival of distal esophageal-gastroesophageal junction adenocarcinoma in patients with and without barrett mucosa.
Portale G; Peters JH; Hagen JA; Demeester SR; Gandamihardja TA; Tharavej C; Hsieh CC; Demeester TR
Arch Surg; 2005 Jun; 140(6):570-4; discussion 574-5. PubMed ID: 15967904
[TBL] [Abstract][Full Text] [Related]
23. Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort.
Krishnamoorthi R; Borah B; Heien H; Das A; Chak A; Iyer PG
Gastrointest Endosc; 2016 Jul; 84(1):40-46.e7. PubMed ID: 26772891
[TBL] [Abstract][Full Text] [Related]
24. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group.
Menke-Pluymers MB; Hop WC; Dees J; van Blankenstein M; Tilanus HW
Cancer; 1993 Aug; 72(4):1155-8. PubMed ID: 8339208
[TBL] [Abstract][Full Text] [Related]
26. Photodynamic therapy for dysplastic Barrett esophagus and early esophageal adenocarcinoma.
Wolfsen HC; Woodward TA; Raimondo M
Mayo Clin Proc; 2002 Nov; 77(11):1176-81. PubMed ID: 12440553
[TBL] [Abstract][Full Text] [Related]
27. Activation of the serine/threonine protein kinase Akt during the progression of Barrett neoplasia.
Sagatys E; Garrett CR; Boulware D; Kelley S; Malafa M; Cheng JQ; Sebti S; Coppola D
Hum Pathol; 2007 Oct; 38(10):1526-31. PubMed ID: 17640711
[TBL] [Abstract][Full Text] [Related]
28. Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma.
Chang JT; Katzka DA
Arch Intern Med; 2004 Jul; 164(14):1482-8. PubMed ID: 15277277
[TBL] [Abstract][Full Text] [Related]
29. Chemoprevention in Barrett's Esophagus: Current Status.
Zeb MH; Baruah A; Kossak SK; Buttar NS
Gastroenterol Clin North Am; 2015 Jun; 44(2):391-413. PubMed ID: 26021201
[TBL] [Abstract][Full Text] [Related]
30. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
[TBL] [Abstract][Full Text] [Related]
31. Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus.
Lord RV; Park JM; Wickramasinghe K; DeMeester SR; Oberg S; Salonga D; Singer J; Peters JH; Danenberg KD; Demeester TR; Danenberg PV
J Thorac Cardiovasc Surg; 2003 Feb; 125(2):246-53. PubMed ID: 12579092
[TBL] [Abstract][Full Text] [Related]
32. [Expression of c-myb in reflux esophagitis, Barrett esophagus and esophageal adenocarcinoma].
Ren CR; Dong L; Guo XY
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Dec; 30(12):2693-5. PubMed ID: 21177182
[TBL] [Abstract][Full Text] [Related]
33. Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma.
Abraham SC; Krasinskas AM; Correa AM; Hofstetter WL; Ajani JA; Swisher SG; Wu TT
Am J Surg Pathol; 2007 Nov; 31(11):1719-25. PubMed ID: 18059229
[TBL] [Abstract][Full Text] [Related]
34. Antireflux surgery, barrett esophagus, and adenocarcinoma: there is still room for doubt.
Jamieson GG
Ann Surg; 2007 Jul; 246(1):22-3. PubMed ID: 17592285
[No Abstract] [Full Text] [Related]
35. Incidence of adenocarcinoma among patients with Barrett's esophagus.
Hvid-Jensen F; Pedersen L; Drewes AM; Sørensen HT; Funch-Jensen P
N Engl J Med; 2011 Oct; 365(15):1375-83. PubMed ID: 21995385
[TBL] [Abstract][Full Text] [Related]
36. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus.
Srivastava A; Hornick JL; Li X; Blount PL; Sanchez CA; Cowan DS; Ayub K; Maley CC; Reid BJ; Odze RD
Am J Gastroenterol; 2007 Mar; 102(3):483-93; quiz 694. PubMed ID: 17338734
[TBL] [Abstract][Full Text] [Related]
37. Risk stratification of Barrett's esophagus: updated prospective multivariate analysis.
Weston AP; Sharma P; Mathur S; Banerjee S; Jafri AK; Cherian R; McGregor D; Hassanein RS; Hall M
Am J Gastroenterol; 2004 Sep; 99(9):1657-66. PubMed ID: 15330898
[TBL] [Abstract][Full Text] [Related]
38. Adenocarcinoma of the esophagus: risk factors and prevention.
Heath EI; Limburg PJ; Hawk ET; Forastiere AA
Oncology (Williston Park); 2000 Apr; 14(4):507-14; discussion 518-20, 522-3. PubMed ID: 10826312
[TBL] [Abstract][Full Text] [Related]
39. Should we worry about the length of Barrett's esophagus?
Shaheen NJ
Gastrointest Endosc; 2005 Nov; 62(5):682-5. PubMed ID: 16246679
[No Abstract] [Full Text] [Related]
40. Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus?
Barthel JS; Kucera ST; Lin JL; Hoffe SE; Strosberg JR; Ahmed I; Dilling TJ; Stevens CW
Gastrointest Endosc; 2010 Feb; 71(2):235-40. PubMed ID: 20003971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
